The popularity of GLP-1 agonists like Wegovy and Ozempic has become a hot topic during Q3 earnings calls, with retail investors rushing to buy Eli Lilly stock after its weight-loss drug received approval. Medical-device investors are rebounding as revised data on obesity drugs provided positive caveats. The surging popularity of weight-loss drugs is expected to have a positive impact on the fitness industry and may boost gym stocks. Abbott Laboratories believes the market is overestimating the impact of weight-loss drugs on sales and sees potential for increased sales in the future.

GLP-1 Agonists: Impact and Rebound